EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

Ginsenoside Rb1 Alleviates DSS-Induced Ulcerative Colitis by Protecting the Intestinal Barrier Through the Signal Network of VDR, PPARγ and NF-κB

Yi Zhou, Xinyu Xiong, Zhe Cheng iD, Zekai Chen, Shizhen Wu, Yan Yu, Yujin Liu, Guang Chen iD, Lingli Li

Drug Design, Development and Therapy · 2024-10 · Volume 18 · 4825-4838

DOI: 10.2147/dddt.s481769 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Design, Development and Therapy, 2024-10. Verfasst von Yi Zhou und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Integrated Traditional Chinese and Western Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Techno…. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Ginsenosides, NF-kappa B, PPAR gamma. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Ginseng (Panax ginseng Meyer) is an herbal medicine used in traditional Chinese medicine (TCM), has the effects of treating colitis and other diseases. Ginsenoside Rb1 (GRb1), a major component of ginseng, modulates autoimmunity and metabolism. However, the mechanism underlying GRb1 treatment of ulcerative colitis (UC) has not yet been elucidated. UC is a refractory inflammatory bowel disease (IBD) with a high recurrence rate, and researches on new drugs for UC have been in the spotlight for a long time.

Methods

Mice with DSS-induced UC were treated with GRb1 or 0.9% saline for 10 days. Colon tissue of UC mice was collected to detect the levels of intestinal inflammatory cytokines and integrity of the intestinal barrier. RNA-seq and network pharmacology were used to predict the therapeutic targets of GRb1 during UC treatment.

Results

GRb1 treatment alleviated intestinal inflammation and improved intestinal barrier dysfunction in UC mice. Specifically, GRb1 downregulated the levels of pro-inflammatory cytokines such as TNF-α and IL-6, while upregulating the level of the anti-inflammatory cytokine IL-10. Additionally, GRb1 treatment increased the levels of tight junction proteins including ZO-1, Occludin, and E-cadherin, which are crucial for maintaining intestinal barrier integrity. Further analyses using RNA-seq and network pharmacology suggested that these effects might involve the regulation of GRb1 in the signal transduction network of VDR, PPARγ, and NF-κB.

Conclusion

The study demonstrated that GRb1 effectively alleviated UC by modulating intestinal inflammation and protecting the integrity of the intestinal barrier through the signal transduction network of VDR, PPARγ, and NF-κB.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colitis, UlcerativeGinsenosidesNF-kappa BPPAR gammaDextran SulfateSignal TransductionReceptors, CalcitriolAnimalsMiceMaleMice, Inbred C57BLIntestinal MucosaDisease Models, Animal

Stichwörter der Autor:innen

ginsenoside Rb1intestinal barriernuclear factor-kappa Bulcerative colitisvitamin D receptor

Substanzen

ginsenoside Rb1GinsenosidesNF-kappa BPPAR gammaDextran SulfateReceptors, Calcitriol

Autor:innen und Institutionen

  • Department of Integrated Traditional Chinese and Western Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, People's Republic of China.
  • College of Acupuncture and Bone Injury, Hubei University of Chinese Medicine, Wuhan, 430061, People's Republic of China.
  • Department of Gastroenterology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, People's Republic of China.
  • Department of Integrated Traditional Chinese and Western Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, People's Republic of China.
  • Department of Traditional Chinese Medicine, Wuhan Fourth Hospital, Wuhan, 430033, People's Republic of China.

ORCID-Profile: Zhe Cheng, Guang Chen

Zitieren

APA

Zhou, Y., Xiong, X., Cheng, Z., Chen, Z., Wu, S., Yu, Y., Liu, Y., Chen, G., & Li, L. (2024). Ginsenoside Rb1 Alleviates DSS-Induced Ulcerative Colitis by Protecting the Intestinal Barrier Through the Signal Network of VDR, PPARγ and NF-κB. Drug Design, Development and Therapy, Volume 18, 4825-4838. https://doi.org/10.2147/dddt.s481769

Vancouver

Zhou Y, Xiong X, Cheng Z, Chen Z, Wu S, Yu Y, et al. Ginsenoside Rb1 Alleviates DSS-Induced Ulcerative Colitis by Protecting the Intestinal Barrier Through the Signal Network of VDR, PPARγ and NF-κB. Drug Design, Development and Therapy. 2024;Volume 18:4825-4838. doi:10.2147/dddt.s481769

BibTeX
@article{Zhou2024,
  author = {Zhou, Yi and Xiong, Xinyu and Cheng, Zhe and Chen, Zekai and Wu, Shizhen and Yu, Yan and Liu, Yujin and Chen, Guang and Li, Lingli},
  title = {Ginsenoside Rb1 Alleviates DSS-Induced Ulcerative Colitis by Protecting the Intestinal Barrier Through the Signal Network of VDR, PPARγ and NF-κB},
  journal = {Drug Design, Development and Therapy},
  year = {2024},
  volume = {Volume 18},
  pages = {4825--4838},
  doi = {10.2147/dddt.s481769}
}
Kostenlos starten →